BofA Securities on BioCryst Pharma (BCRX) 'Stock’s weakness offers particularly attractive entry point'
Tweet Send to a Friend
(Updated - November 4, 2024 2:16 PM EST)
BofA Securities analyst Tazeem Ahmad reiterated a Buy rating and $11.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
BofA Securities analyst Tazeem Ahmad reiterated a Buy rating and $11.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
